9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one
Didanosine
CAS: 69655-05-6
Molecular Formula: C10H12N4O3
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Names and Identifiers
| Name | Didanosine |
| Synonyms | ddino bmy40900 nsc612049 Didansine Didanosine 2.3-Dideoxy dideoxyinosine DDI, Didanosine 2,3-Dideoxyinosine 2',3'-dideoxyinosine 2',3'-Dideoxy Inosine 2',3'-Dideoxy-D-inosine 2',3'-Dideoxy inosine(DDI) 9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one |
| CAS | 69655-05-6 |
| EINECS | 614-994-4 |
| InChI | InChI=1/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16) |
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Physico-chemical Properties
| Molecular Formula | C10H12N4O3 |
| Molar Mass | 236.23 |
| Density | 1.2917 (rough estimate) |
| Melting Point | 193-195°C |
| Boling Point | 193-195 C |
| Specific Rotation(α) | D25 -26.3° (c = 10 in water) |
| Flash Point | 308.5°C |
| Water Solubility | 1-5 g/100 mL at 21 ºC |
| Solubility | Soluble in DMSO (47 mg/mL at 25 °C), chloroform (<1 mg/mL at 23 °C), water (<1 mg/mL |
| Vapor Presure | 1.33E-14mmHg at 25°C |
| Appearance | Powder |
| Color | White to Off-white |
| Merck | 14,3098 |
| BRN | 3619529 |
| pKa | 9.12(at 25℃) |
| Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
| Stability | Stable. Combustible. Incompatible with strong oxidizing agents. |
| Sensitive | Easily absorbing moisture |
| Refractive Index | -28 ° (C=0.34, H2O) |
| MDL | MFCD00077728 |
| Physical and Chemical Properties | Melting Point 175°C water-soluble 1-5g/100 mL at 21°C |
| Use | Anti-cancer drugs, anti-AIDS poisons |
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Risk and Safety
| Hazard Symbols | C - Corrosive |
| Risk Codes | R34 - Causes burns R36/37 - Irritating to eyes and respiratory system. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S27 - Take off immediately all contaminated clothing. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S24/25 - Avoid contact with skin and eyes. |
| WGK Germany | 2 |
| RTECS | NM7460700 |
| HS Code | 29335990 |
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Nature
Open Data Verified Data
white solid, melting point 160-163 °c. [alD5-26, 36(c-10 water);UV maximum absorption: 248nm(pH = 2), 254nm(pH = 12).
Last Update：2024-01-02 23:10:35
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Preparation Method
Open Data Verified Data
inosine was added to an acetonitrile solution of 2-acetoxy-2-methylpropionyl chloride and sodium iodide with stirring. The reaction solution was placed in a saturated aqueous solution of sodium bicarbonate, and extracted with ethyl acetate. The extract was washed with an aqueous solution of sodium bisulfite and a saturated aqueous solution of sodium chloride, and concentrated. The resulting material was dissolved in a mixture of pyridine-acetone (1:2), and a zinc-copper complex was added and stirred. The unreacted zinc-copper complex was removed and treated with an ion exchange resin followed by ammonia/Methanol. The resulting compound was dissolved in aqueous ammonia and hydrogenated in the presence of Raney nickel to give dehydroxyinosine.
Last Update：2022-01-01 09:08:14
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Standard
Authoritative Data Verified Data
This product is 2 ',3'-dideoxyinosine. Calculated as dried product, including C10H12N404 shall not be less than 98.5%.
Last Update：2024-01-02 23:10:35
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Trait
Authoritative Data Verified Data
- This product is white or off-white crystalline powder; Odorless; Unstable in case of acid.
- This product is slightly soluble in water, slightly soluble in methanol, almost insoluble in ethanol; Dissolved in 0.1mol/L sodium hydroxide solution.
specific rotation
take an appropriate amount of this product, accurately weigh it, add water to dissolve and quantitatively dilute it to make a solution containing about 10 mg per lml, and determine it according to law (General rule 0621), the specific rotation is from one 24 ° to one 28 °.
Last Update：2022-01-01 11:34:13
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Introduction
Didanosine is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.
Last Update：2022-10-16 17:28:01
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Use
Open Data Verified Data
It was developed by Squibb Company in Bristol-myers and was first launched in the United States in 1991. Is a nucleoside analog of deoxyadenosine, immunodeficiency virus (HIV) replication inhibitors, used in AIDS. It can inhibit the replication of HIV and is converted into the metabolite dideoxyadenosine triphosphate (ddATP) with antiviral activity under the action of cellular enzymes. Its mechanism of action is similar to Zidovudine. If you can not tolerate zidovudine, or taking zidovudine when there is a significant clinical or immunological deterioration of the use of the product.
Last Update：2022-01-01 09:08:14
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Differential diagnosis
Authoritative Data Verified Data
- a solution containing about 10ug per 1 ml was prepared by dissolving and diluting the appropriate amount of this product and the dehydroxyinosine control, respectively, by adding a flow phase, and used as a sample solution and a reference solution. According to the relevant substances under the chromatographic conditions test, with mobile phase A- mobile phase B(90:10) as mobile phase, take the above two solutions of 20 u1, separate injection of human liquid chromatography, the chromatogram was recorded. The retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the control solution.
- The infrared absorption spectrum of this product should be consistent with the spectrum of the control (Spectrum set 1294B).
Last Update：2022-01-01 11:34:14
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Exam
Authoritative Data Verified Data
Related substances
- take an appropriate amount of this product, dissolve and dilute with mobile phase A- mobile phase B(92:8) as solvent to make A solution containing about 0.5mg per 1 ml, as a test solution (ready to use new); Precision take appropriate amount, quantitative release of Bran with the above solvent to prepare a solution containing about 0.5ug per 1 ml, as a control solution. According to the test of high performance liquid chromatography (General rule 0512), silica gel bonded with eighteen alkyl silane was used as filler (4.6mm × 3.86, 5um ) ; Ammonium acetate solution (g of ammonium acetate, of water was added to dissolve, the pH value was adjusted to 8.0 with ammonia solution, and water was added to ML) as mobile phase A, acetonitrile-methanol (50:50) as mobile Phase B, and gradient elution was carried out according to the following table; The detection wavelength was 254nm. Take appropriate amount of mixed reference substance of dehydroxyinosine impurity, add the above solvent to dissolve and dilute to make a solution containing about 0.5mg per 1 ml, and inject 20u1 into human liquid chromatograph, adjust the mobile phase ratio so that the degree of separation between the peaks of inosine should meet the requirements.
- take the control solution 20 u1 and inject it into the human liquid chromatograph to adjust the detection sensitivity. The signal-to-noise ratio of the main component chromatographic peak should be greater than 20. 20 u1 of the test solution and the control solution were respectively injected into the human liquid chromatograph, and the chromatograms were recorded. If there are impurity peaks in the chromatogram of the test solution, each impurity is located according to the relative retention time in the table below. The product of the peak area of hypoxanthine and its relative correction factor (0.62) should not exceed 5 times (0.5%) of the main peak area of the control solution, the Peak area of 2 '3' anisosine shall not exceed 2 times (0.2%) of the main peak area of the control solution, the peak area of other individual impurities shall not exceed the main peak area of the control solution (0.1%), and the total amount of impurities shall not exceed 1.0%. The peaks in the chromatogram of the test solution which were 0.5 times smaller than the main peak area of the control solution were ignored.
residual solvent
take about 0.5g of this product, precision weighing, top empty bottle, Precision Add dimethyl sulfoxide 5.0ml to dissolve, seal, as a test solution; Another acetonitrile, methane, the right amount of ethanol, methanol, acetone and isopropanol, precision weighing, set in the same measuring flask, with dimethyl sulfoxide quantitative dilution made in each lml containing about 0.5mg of ethanol, acetone 0.5mg, isopropanol 0.5mg, 5ml of a solution of 0.3mg of methanol, 0.041mg of acetonitrile and 0.06mg of dichloromethane was precisely weighed, placed in a headspace bottle, sealed, and used as a reference solution. According to the test for determination of residual solvents (General rule 0861, second method), 6% cyanopropylphenyl-94% dimethylpolysiloxane (or similar polar) was used as the stationary liquid, and the initial temperature was 40°C, which was maintained for 8 minutes, the temperature was increased to 200°C at a rate of 40°C per minute for 10 minutes; The inlet temperature was 200°C; The detector temperature was 250°C; The equilibrium temperature of the headspace bottle was 80°C, the equilibration time was 30 minutes. Take the reference solution into the headspace, the separation degree between the peaks of each component shall meet the requirements. In addition, the reference solution and the test solution were injected in Headspace respectively, and the chromatogram was recorded. According to the external standard method to calculate the peak area, acetonitrile, dichloromethane, ethanol, methanol, acetone and isopropanol residues should be in accordance with the provisions.
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.2%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 10 parts per million of heavy metal when examined by law (General Principles 0821, Law II).
Last Update：2022-01-01 11:34:15
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Content determination
Authoritative Data Verified Data
take about 0.2g of this product, weigh it accurately, add 50ml of glacial acetic acid (if the titration end point is not obvious, add acetic anhydride appropriately, and the ratio of glacial acetic acid to acetic anhydride should not exceed 1:4, the total volume is still 50ml), slightly heat to dissolve, cool, according to the potentiometric titration method (General 0701), with perchloric acid titration solution (O. 1 mol/L) titration, and the results of the titration were corrected with a blank test. Each 1 ml of perchloric acid titration solution (0.1 mol/L) corresponds to 23.62mg of c10h12n403.
Last Update：2022-01-01 11:34:15
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Category
Authoritative Data Verified Data
antiviral drugs.
Last Update：2022-01-01 11:34:16
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 11:34:16
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Dehydroxyinosine enteric-coated capsules
Authoritative Data Verified Data
This product contains, to hydroxyl inosine (C10H12N403) should be 90.0% to 110.0% of the label.
trait
The content of this product is white or white coated pellets or granules.
identification
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the control solution.
- take an appropriate amount of fine powder under the content determination item of this product (about 0.lg of dehydroxyinosine), put it in a 100ml measuring flask, add an appropriate amount of water, and fully shake to dissolve dehydroxyinosine, dilute with water to the scale, shake, filter, take the filtrate, dilute with water to make a solution containing dehydroxyinosine l0ug per 1 ml, according to UV-visible spectrophotometry (General 0401) it was determined that there was a maximum absorption at a wavelength of 249mn and a minimum absorption at a wavelength of 222nm.
examination
- relevant substances: Take appropriate amount of fine powder of this product, precisely weigh it, add mobile phase A- mobile phase B(92:8) to dissolve and dilute to make A solution containing 0.5mg of dehydroxyinosine per 1 ml, shake, filter, take the filtrate as a test solution (ready to use new), take an appropriate amount of precision, quantitative dilution with the above solvent to make a solution containing about 0.5ug per lml, as a control solution. If there are impurity peaks in the chromatogram of the test solution, each impurity is located according to the relative retention time in the following table of the hydroxyinosine. The product of the peak area of hypoxanthine and its relative correction factor (0.62) should not exceed 7 times (0.7%) of the main peak area of the control solution ', the Peak area of 3' anmiinosine shall not exceed 2 times (0.3%) of the main peak area of the control solution, the peak area of other individual impurities shall not exceed the main peak area of the control solution (0.2% ), and the total amount of impurities shall not exceed 1.2%. The peaks in the test solution which were 0.5 times smaller than the main peak area of the control solution were ignored.
- dissolution of this product, according to the dissolution and release determination method (General 0931 first method 2), first 0.100 ml of a 1 mol/L hydrochloric acid solution was used as a dissolution medium at a rotation speed of revolutions per minute. After 2 hours, 10ml of the solution was taken as a test solution (1). The acid solution in each dissolution Cup was discarded, and then a phosphate buffer solution (pH 0.51) preheated to 37 ° C. ± 6.8 was added to each dissolution Cup. 1 mol/L hydrochloric acid solution -0.2mol/L sodium phosphate solution (3:1), if necessary, adjust the pH value to 6.8 with 2mol/L hydrochloric acid solution or 2mol/L sodium hydroxide solution to, and continue to operate according to law. After 45 minutes, take the solution and filter it, take 5ml of continuous filtrate accurately, put it in a 50ml measuring flask, dilute it to scale with the above buffer, shake it well, and use it as Test Solution (2), after the empty capsule is cleaned and evaporated with ethanol, the solution prepared according to the preparation method of the test solution (1) is used as the blank solution (1), and the test solution (1) is taken, with the blank solution (1) as the blank, the absorbance was measured at the wavelength of 249nm by ultraviolet-visible spectrophotometry (General rule 0401), and the absorbance value should not exceed 0. 52 (10% of the labeled amount). Take the sample solution (2 ), take the above buffer solution as a blank, and measure the absorbance at the wavelength of 249mn by ultraviolet-visible spectrophotometry (General rule 0401); in addition, an appropriate amount of dehydroxyinosine reference substance was accurately weighed, dissolved and quantitatively diluted with the above buffer solution to prepare a solution containing about 10ug per 1 ml, which was determined by the same method to calculate the dissolution amount of each particle. The limit is 80% of the labeled amount and shall be in accordance with the provisions.
- others should comply with the relevant provisions under the capsule (General 0103).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler; Ammonium acetate solution (take ammonium acetate 3.86g, add water to dissolve 8.0, adjust the pH value to with ammonia water, water was added to 1000ml)-acetonitrile-methanol (90:5:5) as mobile phase; The detection wavelength was 254nm. The number of theoretical plates shall not be less than 6000 based on the calculated value of dehydroxyinosine peak. The separation degree between dehydroxyinosine peak and adjacent impurity peak shall meet the requirements.
- the contents were mixed evenly and ground finely under the item of difference in loading amount, and an appropriate amount of fine powder (equivalent to 25mg of dehydroxyinosine) was accurately weighed, add the mobile phase to dissolve and quantitatively dilute to make a solution containing 10ug of dehydroxyinosine per lml, filter, take the continued filtrate as the test solution, take 2Ou1 injection of human liquid chromatograph with precision, the chromatogram was recorded, and appropriate amount of hydroxyinosine control was measured with the same method. According to the external standard method to calculate the peak area, that is.
category
Same as dehydroxyinosine.
specification
0.lg
storage
light shielding, sealed storage.
Last Update：2022-01-01 11:34:17
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one - Dehydroxyinosine chewable tablets
Authoritative Data Verified Data
This product contains hydroxyl inosine (C10H12N403) should be 90.0% to 110.0% of the label amount.
trait
This product is white-like tablets.
identification
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- Take appropriate amount of fine powder of this product (about 5mg equivalent to dehydroxyinosine), put it in 50ml expensive bottle, add appropriate amount of water, shake to dissolve dehydroxyinosine, dilute it to the scale, filter it, the filtrate was diluted with water to make a solution containing about 10ug of dehydroxyinosine per 1 ml, which was determined by UV-Vis spectrophotometry (General 0401) and showed maximum absorption at the wavelength of 249nm, there is minimal absorption at a wavelength of 222nm.
examination
- Related Substances: Take appropriate amount of fine powder of this product for precision weighing, add mobile phase A- mobile phase B(92:8) dissolve and dilute to make a solution containing 0.5mg of dehydroxyinosine per lm l, shake well, filter, and take the continued filtrate as a test solution (ready to use new system), take appropriate amount with precision, A solution containing about 0.5ug per 1 ml was prepared as a control solution by quantitative dilution with the above solvent. If there are impurity peaks in the chromatogram of the test solution, each impurity is located according to the relative retention time in the following table of the hydroxyinosine. The product of the peak area of hypoxanthine and its relative correction factor (0.62) shall not exceed 7 times (0.7%) of the main peak area of the control solution, the Peak area of anhydroinosine shall not exceed 2 times (0.3%) of the main peak area of the control solution, the peak area of other individual impurities shall not exceed the main peak area of the control solution (0.2%), and the total amount of impurities shall not exceed 1.2%. The peaks in the chromatogram of the test solution which were 0.5 times smaller than the main peak area of the control solution were ignored.
- Content uniformity take 1 tablet of this product (25mg specification), put it in a 100ml measuring flask, add an appropriate amount of mobile phase, make the dehydroxyinosine completely dissolved by ultrasound, and then put it at room temperature, then dilute to scale with mobile phase, shake, filter, take appropriate amount of filtrate with precision, dilute quantitatively with mobile phase to make solution containing about 10ug per lml, and determine according to the method under the content determination item, calculate the content of each tablet, should be in accordance with the provisions (General 0941).
- acid preparation: take about 0.5g of the fine powder under the content determination item, weigh it accurately, put it in a 250ml plug Erlenmeyer flask, and add 100ml of hydrochloric acid titration solution (0.1mol/L), plug, continuously shake at 37°C for 20 minutes, filter, take the filtrate 25ml, add 2 drops of bromophenol blue indicator solution, and use sodium hydroxide titration solution (O.lmol/L) titration. The volume of hydrochloric acid titrant (0.1 mol/L) consumed per tablet should not be less than 170ml.
- Heavy metals take this product l.Og, inspection according to law (General Principles 0821 second law), containing heavy metals shall not exceed 20 parts per million.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
- determined by high performance liquid chromatography (General 0512),
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler; Ammonium acetate solution (take ammonium acetate 3.86g, add water to dissolve 8.0, adjust the pH value to with ammonia water, water was added to 1000ml)-acetonitrile-methanol (90:5:5) as mobile phase; The detection wavelength was 254nm. The number of theoretical plates shall not be less than 6000 based on the calculated value of dehydroxyinosine peak. The separation degree between dehydroxyinosine peak and adjacent impurity peak shall meet the requirements.
- determination of this product 20 tablets, precision weighing, fine grinding, precision weighing fine powder appropriate amount (equivalent to 25mg), add the mobile phase to dissolve and quantitatively dilute to make a solution containing 10ug of dehydroxyinosine per lml, filter, take the continued filtrate as the test solution, and inject 20u1 into the human liquid chromatograph with precision measurement, the chromatogram was recorded, and appropriate amount of hydroxyinosine reference was removed, then the sample was weighed accurately and determined by the same method. According to the external standard method to calculate the peak area, that is.
category
Same as dehydroxyinosine.
specification
(l)25mg (2)100mg
storage
light-shielded, sealed, and stored in a dry place.
Last Update：2022-01-01 11:34:18
![9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydro-6H-purin-6-one](http://res.chembk.com/assets/str/2d/6/69/69655-05-6.png)
Supplier List
Spot supply
Product Name: Didanosine Visit Supplier Webpage Request for quotationCAS: 69655-05-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: 2',3'-Dideoxyinosine Request for quotation
CAS: 69655-05-6
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
CAS: 69655-05-6
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
Spot supply
Product Name: Didanosine Visit Supplier Webpage Request for quotationCAS: 69655-05-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: 2',3'-Dideoxyinosine Request for quotation
CAS: 69655-05-6
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
CAS: 69655-05-6
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
View History